BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Pain Therapeutics (PTIE) Receives $5,000,000 Payment from King Pharmaceuticals┬«, Inc.


1/28/2011 7:18:35 AM

SAN MATEO, Calif., Jan. 28, 2011 (GLOBE NEWSWIRE) -- Pain Therapeutics, Inc. (Nasdaq:PTIE - News) today announced that it had received a $5,000,000 milestone payment from King Pharmaceuticals, Inc. (NYSE:KG - News), its exclusive commercial partner for abuse-resistant prescription pain medications.

Payment was made in connection with the acceptance by the U.S. Food & Drug Administration (FDA) of an investigational new drug application, or IND, for abuse-resistant oxymorphone. The IND application was submitted by Pain Therapeutics and accepted by FDA within 30 days of its submission.

Like REMOXY(R) (controlled-release oxycodone), Pain Therapeutics' novel formulation of oxymorphone is specifically designed to resist common methods of prescription drug abuse.

On October 11, 2010, King entered into an agreement and plan of merger with Pfizer Inc. (NYSE:PFE - News), the world's largest research-based pharmaceutical company, pursuant to a tender offer. The tender offer is ongoing.

REMOXY(R) is a registered trademark of Pain Therapeutics, Inc.

About Pain Therapeutics, Inc.

Pain Therapeutics, Inc. is a biopharmaceutical company that develops novel drugs. In addition to REMOXY, the Company has three other drug candidates in clinical programs. These include a novel monoclonal antibody--based treatment against metastatic melanoma. The Company is also developing a new treatment for patients with hemophilia, a genetic disorder in which patients are unable to stop bleeding. For more information, please see http://www.paintrials.com

Forward--Looking Statements

This press release contains forward--looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 (the "Act"). When used in this press release, the words "intend", "expect", "believe" and similar expressions are intended to identify forward--looking statements. Examples of forward--looking statements in this press release include statements concerning, among other items, expectations regarding the drug's ability to resist common methods of abuse; and the pending acquisition of King by Pfizer. The Company disclaims any intent or obligation to update these forward--looking statements, and claims the protection of the Safe Harbor for forward--looking statements contained in the Act. Such statements are based on management's current expectations, but actual results may differ materially due to various factors. Such statements involve risks and uncertainties, including, but not limited to, those risks and uncertainties relating to difficulties or delays in regulatory approval of REMOXY; unexpected adverse side effects or inadequate therapeutic efficacy of the Company's drug candidates; the uncertainty of delay or abandonment of the announced acquisition of King by Pfizer; the uncertainty of patent protection for the Company's intellectual property or trade secrets; the timing and receipt of funds from King; the potential for abuse resistant pain medications to be developed by competitors and potential competitors to the Company; and the potential for Pfizer, if the acquisition of King is completed, to hold rights to products or product candidates that may be competitive to REMOXY. For further information regarding these and other risks related to the Company's business, investors should consult the Company's filings with the Securities and Exchange Commission.

Contact:

Judy Ishida Administrative Manager Pain Therapeutics, Inc. IR@paintrials.com 650-645-1924

Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES